Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

2017; Bentham Science Publishers; Volume: 17; Issue: 7 Linguagem: Inglês

10.2174/1568009617666170330120452

ISSN

1873-5576

Autores

Sarah Sammons, Donna L. Topping, Kimberly Blackwell,

Tópico(s)

Breast Cancer Treatment Studies

Resumo

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Keywords: Abemaciclib, advanced breast cancer, CDK4/6 inhibitor, hormone receptor-positive, palbociclib, ribociclib.

Referência(s)